Wet age-related macular degeneration (wet AMD) is one of the leading causes of severe vision loss among adults over 60. It occurs when abnormal blood vessels grow beneath the retina’s macula, leak fluid or blood, and cause rapid damage to central vision. Although the condition can progress quickly, modern medical advances—especially anti-VEGF treatments pioneered by companies like Allergan—have transformed how this disease is managed and controlled.

What Happens in Wet AMD

In healthy eyes, the macula provides sharp, detailed central vision. In wet AMD, excessive production of vascular endothelial growth factor (VEGF) triggers the growth of fragile, leaky blood vessels beneath the macula. The leakage causes swelling, scarring, and eventually central vision loss. Without timely treatment, patients may experience permanent blindness in the affected eye.

Risk Factors and Early Symptoms

Risk factors for wet AMD include aging, genetic susceptibility, smoking, high blood pressure, and prolonged exposure to ultraviolet light. People who already have the dry form of AMD are at higher risk of progressing to the wet type. Early symptoms often include blurred or distorted vision, wavy lines on straight objects, and dark or blank spots in the center of vision. Regular eye exams are essential, as early detection significantly improves treatment success.

The Role of Allergan Anti-VEGF Therapy

Allergan’s research into anti-VEGF therapy has played an important role in the development of targeted treatments for wet AMD. Anti-VEGF drugs work by blocking the VEGF protein, preventing new abnormal blood vessels from forming under the retina. This helps stop leakage, reduce swelling, and stabilize or even improve vision.

One investigational Allergan treatment, Abicipar Pegol, developed in partnership with Molecular Partners, was designed to provide longer-lasting control of the disease compared with traditional injections. By extending dosing intervals, it aimed to reduce the number of eye injections needed each year while maintaining strong visual outcomes—an innovation that could make treatment more manageable for patients.

Other Anti-VEGF Options and Treatment Approach

Current standard anti-VEGF medications include ranibizumab (Lucentis), aflibercept (Eylea), and bevacizumab (Avastin). These drugs are delivered via small intravitreal injections directly into the eye, typically once every 4–8 weeks. Many patients experience stabilization or noticeable improvement in vision with consistent use.

Because wet AMD can worsen quickly, treatment should begin as soon as it’s diagnosed. Regular follow-up appointments help doctors monitor the retina and adjust therapy as needed. New delivery systems and sustained-release implants are also under study to further reduce treatment burden.

Living With Wet AMD

While wet AMD remains a chronic condition, early and consistent anti-VEGF treatment allows most patients to maintain functional vision and independence. Complementary steps—such as quitting smoking, following a diet rich in antioxidants, and protecting eyes from UV exposure—also help preserve eye health. Vision-rehabilitation programs and low-vision aids can support daily activities and improve quality of life.

In Summary
The development of Allergan’s anti-VEGF therapies represents a major milestone in combating wet AMD. By targeting the root cause—abnormal blood vessel growth—these treatments have dramatically changed outcomes for millions of patients worldwide. With early diagnosis, regular injections, and proper care, people with wet AMD can now look forward to preserving their sight and living more confidently despite the disease.